Jack Cheng
Seminars
Wednesday 28th January 2026
Combining Brain-Penetrant CHK1 & PRMT5 Inhibitors to Enhance Efficacy & Optimize Pharmacodynamics in Preclinical Models
4:15 pm
• See the rationale behind PharmaEngine’s combination of CHK1 and PRMT5 inhibitors with preclinical examples
• Understanding alternation of pharmacodynamic markers of CHK1 and PRMT5 post corresponding inhibitor treatments
• Discovering combinations of CHK1 or PRMT5 inhibitors to standard of cares (SoCs) in corresponding indications
